Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Tecartus First Gene Therapy FDA Approved for Patients with Mantle-Cell Lymphoma

October 2020 Vol 6 No 5

In July 2020, the FDA approved Tecartus (brexucabtagene autoleucel; from Kite Pharma), a CAR T-cell therapy, for the treatment of adults with mantle-cell lymphoma whose disease has not responded to or has relapsed after other therapies. Tecartus is the first gene therapy approved by the FDA specifically for the treatment of patients with mantle-cell lymphoma, a rare type of B-cell non-Hodgkin’s lymphoma.

Commenting on this FDA approval, Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research, said, “This approval is yet another example of customized treatments that use a patient’s own immune system to help fight cancer, while using a scientific advance in this promising new area of medicine. We’re seeing continued advances in the field of gene therapy and remain committed to supporting innovation in this promising new area of medicine.”

The FDA approved Tecartus based on results from a multicenter clinical trial of 60 adults with relapsed or refractory mantle-cell lymphoma who were followed for 6 months or longer after their first response to treatment. Overall, 87% of the patients had a response to therapy with Tecartus, including 62% of patients who reached remission (no cancer).

Like all gene therapies, Tecartus is made from the patient’s own immune system by collecting the patient’s cells and genetically modifying them to target the lymphoma cells. These modified T-cells are then infused back into the patient.

The most common side effects reported with Tecartus were serious infections, low blood cell counts, and a weakened immune system. Side effects usually appear within the first 1 to 2 weeks after treatment, but some adverse reactions may occur later. Of note, Tecartus can lead to cytokine release syndrome, a life-threatening condition.

Recommended For You